Trump’s sudden cut in substance testing is ‘going to kill people’, experts warn

Lead

The Trump administration has moved to restrict the use of federal funds for fentanyl test strips, a decision that harm reduction experts and advocates warn could have fatal consequences for people at risk of overdose. The policy, enacted through an open letter from the Substance Abuse and Mental Health Services Administration (SAMHSA), orders an end to the use of its funding for all substance testing strips, including those designed to detect fentanyl, xylazine, and medetomidine, according to reports from The Guardian.

The move marks a significant shift in federal drug policy, halting a practice first permitted in 2021 under the Biden administration, which allowed federal funds to be used for fentanyl test strips as part of an effort to reduce overdose deaths from the potent synthetic opioid.

Coverage Comparison

Coverage of the policy change has been primarily carried by The Guardian, which has reported on the issue in two separate articles. Both reports highlight the concerns of harm reduction advocates and experts, who argue that restricting access to test strips could increase overdose risks. The reports also note an apparent contradiction: the White House's National Drug Control Strategy, also published recently, explicitly supports the use of rapid test strips to detect fentanyl and other drugs.

The Guardian's reporting frames the decision as part of a broader pattern of the Trump administration rolling back harm reduction interventions, including a previous attempt to block "never use alone" messaging by the Centers for Disease Control and Prevention (CDC). The reports also mention proposed budget cuts that would strip away $10bn in funding for addiction and overdose prevention and research, as well as Medicaid cuts under the One Big Beautiful Bill Act, which experts warn could lead to hospital closures and reduced availability of addiction treatment.

While the facts are consistent across the two articles, the second report adds context about the ideological stance of the administration, quoting advocates who describe the decision as a "clear shift away from harm reduction." Neither report provides comment from the administration beyond the SAMHSA letter's justification that test strips "facilitate illicit drug use" and are "incompatible with federal laws."

Key Claims

• The SAMHSA issued an open letter in April ordering an end to the use of its funding for all substance testing strips, including fentanyl test strips. This claim is reported by both Guardian articles.
• The restriction could substantially reduce the availability of drug-testing strips for people at risk of overdose, according to harm reduction advocates.
• Maia Szalavitz, a New York Times columnist and author of "Undoing Drugs", is quoted as saying "It's going to kill people," and describing Robert F Kennedy Jr as "the worst thing that has happened to the addictions field for decades and decades." This quote carries strong emotional weight but reflects the advocate's personal opinion.
• Dr Nabarun Dasgupta, director of the University of North Carolina's Opioid Data Lab, said defunding test strips "is a win for the cartels," as it would take away people's ability to identify impure products and flag them to dealers. This claim is attributed to a single source and has not been independently verified.
• The White House's National Drug Control Strategy supports the use of rapid test strips to detect fentanyl and other drugs, creating a contradiction with the SAMHSA policy. This claim is based on the text of the strategy as reported, though the specific language is not quoted.
• Proposed budget cuts, reportedly $10bn, would undermine overdose prevention efforts, according to the Guardian. This figure is cited in one article and has not been corroborated by other sources.
• The 2021 decision by the Biden administration to permit federal funding for fentanyl test strips was made "in an effort to reduce overdose deaths," as reported by The Guardian. This is a historical fact that has been previously reported.

Perspectives

Harm reduction advocates and public health experts are critical of the policy, arguing that test strips are a proven tool to help people avoid overdoses and that restricting them will lead to preventable deaths. They view the administration's ideological stance against harm reduction as misguided and dangerous.

The Trump administration's rationale, as stated in the SAMHSA letter, is that testing strips are "incompatible with federal laws" and "facilitate illicit drug use." This perspective suggests a focus on abstinence-based approaches rather than risk reduction. No official from the administration is quoted directly in the available reporting, limiting the ability to fully understand the policy's intent.

The apparent contradiction between the SAMHSA policy and the National Drug Control Strategy suggests a lack of coordination between government agencies, as noted by the Guardian. This could indicate that the policy is not a unified administration stance but rather a departmental decision that may face internal or external challenges.

As the situation develops, the impact of the test strip ban on overdose rates will not be immediately clear. However, the urgency expressed by experts highlights the high stakes involved in this policy shift.